Muir OS

Radial, New York, NY.

10 papers · 11 preprints

ArticleMescaline

Psychedelic Therapy: A Primer for Primary Care Clinicians-Mescaline.

Tabaac BJ, Shinozuka K, Fadel M +3

Psychedelic Therapy: A Primer for Primary Care Clinicians-5-Methoxy-N,N-Dimethyltryptamine.

Tabaac BJ, Shinozuka K, Weisman A +3

PreprintMescaline

Psychedelic Therapy: A Primer for Primary Care Clinicians—Mescaline

Tabaac BJ, Shinozuka K, Fadel +3

Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT)

Tabaac BJ, Shinozuka K, Weisman A +3

PreprintKetamine

Mapping the Use of Ketamine in Treatment-Resistant Depression and Other Psychiatric Disorders: A Scoping Review of Practice Patterns, Efficacy, and Patient Demographic Trends

Aslam A, Shinozuka K, Muir OS +1

ArticleIbogaine

Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.

Cherian K, Shinozuka K, Tabaac BJ +5

ArticleKetamine

Psychedelic Therapy: A Primer for Primary Care Clinicians-The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics.

Muir OS, Shinozuka K, Beutler BD +5

Psychedelic Therapy: A Primer for Primary Care Clinicians-3,4-Methylenedioxy-methamphetamine (MDMA).

Shinozuka K, Tabaac BJ, Arenas A +5

ArticleAyahuasca

Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca.

Shinozuka K, Tabaac BJ, Arenas A +5

ArticlePsilocybin

Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.

Tabaac BJ, Shinozuka K, Arenas A +5

ArticleKetamine

Psychedelic Therapy: A Primer for Primary Care Clinicians-Ketamine.

Evans VD, Arenas A, Shinozuka K +5

Psychedelic Therapy: A Primer for Primary Care Clinicians-Lysergic Acid Diethylamide (LSD).

Beutler BD, Shinozuka K, Tabaac BJ +5

ArticlePsilocybin

Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.

Tabaac BJ, Shinozuka K, Arenas A +5

PreprintKetamine

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VIII. The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics

Muir OS, Shinozuka K, Beutler BD +5

PreprintKetamine

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VII. Ketamine

Evans VD, Arenas A, Shinozuka K +5

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VI. 3,4-methylenedioxy-methamphetamine (MDMA)

Shinozuka K, Tabaac BJ, Arenas A +5

PreprintPsilocybin

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview

Tabaac BJ, Shinozuka K, Arenas A +5

PreprintIbogaine

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part V. Ibogaine

Cherian K, Shinozuka K, Tabaac BJ +5

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part II. Lysergic acid diethylamide (LSD)

Beutler BD, Shinozuka K, Tabaac BJ +5

PreprintPsilocybin

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part IV. Psilocybin

Tabaac BJ, Shinozuka K, Arenas A +5

PreprintAyahuasca

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part III. N,N-dimethyltryptamine (DMT) and Ayahuasca

Shinozuka K, Tabaac BJ, Arenas A +5